Sulesomab

DB13976ApprovedProtein Based Therapies

Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.

Also known as
IMMU-MN3 · Immunoglobulin G1 (mouse monoclonal IMMU-MN3 Fab' fragment gamma-chain anti-human NCA-90 granulocyte cell antigen), disulfide with mouse monoclonal IMMU-MN3 light chain

Resolves to

Compound
UNII709B6VM65PCAS167747-19-5
Clinical / RWD
ATCV09HA04

What you can answer from here — as of July 17, 2026

382Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 12 drug categories
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of Sulesomab, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In